Genus plc (GNS) AI Stock Analysis

• Market Cap: £1.71B
• Dividend Yield: 1.25%
• Average Volume (3M): 171.79K
• Price to Earnings (P/E): 87.9
• Beta (1Y): 1.78
• Revenue Growth: 0.60%
• EPS Growth: 143.39%
• Country: UK
• Employees: 3,500
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.27
• Shares Outstanding: 66,537,766
• 10 Day Avg. Volume: 120,789
• 30 Day Avg. Volume: 171,792
• PEG Ratio: 0.49
• Price to Book (P/B): 2.83
• Price to Sales (P/S): 2.00
• P/FCF Ratio: 27.73
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £3,050.00
• Price Target Upside: 20.79% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 69 Neutral
• Price Target: 2,836.00p ▲(12.32% Upside)

Genus plc's overall stock score is driven by strong corporate events and solid financial performance. However, technical indicators suggest caution due to potential overbought conditions, and the high P/E ratio indicates possible overvaluation.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective business strategies, supporting long-term financial health and expansion.

Operational Efficiency

Strong operational efficiency reflects effective cost control and resource management, enhancing profitability and competitive positioning.

Market Position

As a leader in animal genetics, Genus benefits from a strong market position, leveraging advanced technologies to maintain a competitive edge.

Negative Factors

Profitability Margins

Low net profit margins may limit profitability, indicating a need for better cost control or increased revenue to improve financial performance.

Cash Flow Volatility

Volatile free cash flow can hinder investment capabilities and financial planning, affecting long-term growth and stability.

Debt Levels

While moderate, debt levels require careful management to ensure they do not become burdensome, potentially impacting financial flexibility.

Genus plc Business Overview & Revenue Model

Company Description

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers semen sexing, in reproductive, and other technical services to farmers. Genus plc has a strategic collaboration with Beijing Capital Agribusiness Co. Ltd to pursue the porcine reproductive respiratory syndrome virus resistant regulatory and development work in China. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.

How the Company Makes Money

Genus generates revenue through several key streams. Primarily, the company earns money from the sale of genetic materials, such as semen and embryos, to livestock producers. These products are essential for breeding programs aimed at improving animal traits such as growth efficiency, disease resistance, and reproductive performance. Additionally, Genus offers genetic services, including data analysis and breeding consultancy, which provide added value to their customers. Significant partnerships with agricultural producers and cooperatives enhance Genus's market reach and contribute to its earnings. The company also benefits from research and development investments that lead to innovation in genetic technologies, ensuring a competitive edge in the animal breeding industry.

Genus plc Financial Statement Overview

Summary

Genus plc exhibits strong revenue growth and operational efficiency, with a solid balance sheet. However, profitability margins and cash flow stability present areas for improvement.

Income Statement

Genus plc has demonstrated consistent revenue growth over the years, with a notable increase in the latest period. The gross profit margin is strong, indicating efficient cost management. However, the net profit margin is relatively low, suggesting potential areas for cost optimization or revenue enhancement. The EBIT and EBITDA margins are healthy, reflecting good operational efficiency.

Balance Sheet

The company's debt-to-equity ratio is moderate, indicating a balanced approach to leveraging. Return on equity has seen some fluctuations but remains positive, suggesting that the company is generating returns on shareholders' investments. The equity ratio is stable, showing a solid capital structure.

Cash Flow

Genus plc's cash flow from operations is robust, but free cash flow has experienced volatility, which could impact future investments or debt repayments. The operating cash flow to net income ratio is healthy, indicating good cash generation relative to reported earnings. However, the free cash flow to net income ratio suggests room for improvement in cash conversion efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	672.80M	672.80M	668.80M	689.70M	593.40M	574.30M
Gross Profit	672.80M	672.80M	178.70M	239.30M	226.00M	232.20M
EBITDA	85.10M	93.70M	73.70M	87.50M	79.80M	82.30M
Net Income	19.30M	19.30M	7.90M	33.30M	40.90M	47.30M
Balance Sheet
Total Assets	899.00M	899.00M	1.03B	1.01B	1.02B	851.00M
Cash, Cash Equivalents and Short-Term Investments	48.00M	48.00M	42.50M	36.30M	38.80M	46.00M
Total Debt	265.90M	265.90M	291.20M	232.10M	223.80M	151.60M
Total Liabilities	423.00M	423.00M	485.00M	440.30M	445.80M	354.40M
Stockholders Equity	475.60M	475.60M	548.20M	569.40M	578.50M	498.10M
Cash Flow
Free Cash Flow	59.90M	48.60M	5.10M	15.20M	-7.80M	38.80M
Operating Cash Flow	73.30M	67.20M	29.80M	50.40M	34.30M	67.50M
Investing Cash Flow	-22.50M	-13.80M	-19.30M	-30.90M	-67.20M	-46.70M
Financing Cash Flow	-44.00M	-46.60M	-2.80M	-18.20M	21.90M	-14.20M

Genus plc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2525.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:GNS, the sentiment is Positive. The current price of 2525 is below the 20-day moving average (MA) of 2569.50, above the 50-day MA of 2518.90, and above the 200-day MA of 2287.41, indicating a bullish trend. The MACD of 13.86 indicates Negative momentum. The RSI at 57.91 is Neutral, neither overbought nor oversold. The STOCH value of 51.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:GNS.

Genus plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BVXP	75 Outperform	£98.75M	13.01	64.40%	8.33%	-3.61%	-6.35%
GNS	69 Neutral	£1.71B	87.94	3.77%	1.25%	0.60%	143.39%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ONT	51 Neutral	£1.34B	-9.43	-26.01%	―	22.03%	20.01%
FAB	44 Neutral	£17.05M	-10.07	-164.37%	―	-11.43%	23.40%
4BB	41 Neutral	£95.23M	-6.19	-209.34%	―	198.49%	-26.66%
OBD	38 Underperform	£9.87M	-0.25	-407.49%	―	72.17%	79.03%

Genus plc Corporate Events

Genus plc Grants Restricted Share Units to Executive Team

Genus plc announced the granting of Restricted Share Units under its 2025 Long Term Incentive Plan to its Executive Directors and Executive Leadership Team. These awards, which will vest in September 2028, are part of the company’s strategy to align leadership incentives with long-term shareholder value, potentially impacting the company’s operational focus and stakeholder interests.

The most recent analyst rating on (GB:GNS) stock is a Buy with a £3050.00 price target. To see the full list of analyst forecasts on Genus plc stock, see the GB:GNS Stock Forecast page.

Genus plc Secures Shareholder Approval for All AGM Resolutions

Genus plc announced that all resolutions proposed at its Annual General Meeting (AGM) on 19 November 2025 were passed. The resolutions included both ordinary and special resolutions, covering topics such as director elections, remuneration policies, and share allotment authorities. The approval of these resolutions reflects strong shareholder support and positions the company to continue its strategic initiatives effectively.

The most recent analyst rating on (GB:GNS) stock is a Hold with a £2646.00 price target. To see the full list of analyst forecasts on Genus plc stock, see the GB:GNS Stock Forecast page.

Genus plc Reports Strong Start to FY26 with Promising Outlook

Genus plc reported a strong start to the fiscal year, with expectations for FY26 adjusted profit before tax to exceed market forecasts. The company’s PIC division showed robust growth across all regions, particularly in China, while the ABS division experienced lower-than-expected profits due to phasing, with improvements anticipated in the second half. The ongoing Value Acceleration Programme is progressing as planned, and the company remains confident in its growth model and future performance.

The most recent analyst rating on (GB:GNS) stock is a Hold with a £2646.00 price target. To see the full list of analyst forecasts on Genus plc stock, see the GB:GNS Stock Forecast page.

Genus plc Strengthens Board with New Non-Executive Director Appointments

Genus plc has announced the appointment of Dr. Celia Baxter and Dr. Robert Reiter as Non-Executive Directors, effective November 19, 2025, and January 1, 2026, respectively. Dr. Baxter brings extensive experience in human resources and strategic management, while Dr. Reiter offers significant expertise in genetics and gene editing technology. These appointments are expected to enhance Genus’s strategic and scientific capabilities, potentially strengthening its position in the animal genetics industry.

The most recent analyst rating on (GB:GNS) stock is a Hold with a £2646.00 price target. To see the full list of analyst forecasts on Genus plc stock, see the GB:GNS Stock Forecast page.

Genus plc Updates Share Capital Information

Genus plc, a company listed on the London Stock Exchange under the ticker GNS, has announced that as of October 31, 2025, its issued share capital consists of 66,537,765 ordinary shares, each with voting rights. This update is relevant for shareholders who need to calculate their interest in the company according to the FCA’s Disclosure Guidance and Transparency Rules.

The most recent analyst rating on (GB:GNS) stock is a Hold with a £2646.00 price target. To see the full list of analyst forecasts on Genus plc stock, see the GB:GNS Stock Forecast page.

Genus plc Releases 2025 Annual Report and AGM Details

Genus plc has distributed its Annual Report for 2025, along with the Notice of its Annual General Meeting and the Form of Proxy, to its shareholders. These documents are accessible on the company’s website and have been submitted to the National Storage Mechanism for public inspection. The Annual General Meeting is scheduled for November 19, 2025, in London, where proposed resolutions will be discussed. This announcement ensures transparency and regulatory compliance, potentially impacting shareholder engagement and corporate governance.

The most recent analyst rating on (GB:GNS) stock is a Hold with a £2646.00 price target. To see the full list of analyst forecasts on Genus plc stock, see the GB:GNS Stock Forecast page.

Genus plc Updates Share Capital and Voting Rights

Genus plc, a company listed on the London Stock Exchange, has announced that as of September 30, 2025, its issued share capital comprises 66,537,454 ordinary shares, each with voting rights. This update is relevant for shareholders calculating their interests under the FCA’s Disclosure Guidance and Transparency Rules.

The most recent analyst rating on (GB:GNS) stock is a Hold with a £2482.00 price target. To see the full list of analyst forecasts on Genus plc stock, see the GB:GNS Stock Forecast page.